Skip to content
Biodatica
Start free

Great Novel Therapeutics Biotech & Medicals Corporation

Kaohsiung City

OncologyPhase II
Compare Sign in to watch

What changed

Phase II trial registered: Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

1w agoTrial registeredJul 7, 2026Source filing (opens the source filing in a new tab)

Momentum

81no change

Momentum 81 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,012 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Aug 1, 2025

    AIMAS, Developmental Coordination Disorder · ACTIVE_NOT_RECRUITING · sponsor: Chang Gung Memorial Hospital · Smart Steps to Growth: Unleashing AI for Assessing Motor Skills in School Children

    ClinicalTrials.gov · NCT07083726 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Oct 18, 2024

    Relapsed or Refractory Peripheral T-cell Lymphoma · RECRUITING · sponsor: Great Novel Therapeutics Biotech & Medicals Corporation · Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

    ClinicalTrials.gov · NCT05833724 (opens the source filing in a new tab)

  3. Trial

    Study registered

    Jul 1, 2024

    Genetics, Life Participation · COMPLETED · sponsor: Chang Gung Memorial Hospital · Developmental Trajectory of Gene and Life Participation in Children With Developmental Delay

    ClinicalTrials.gov · NCT06674928 (opens the source filing in a new tab)

  4. Trial

    PHASE1/PHASE2 registered

    Apr 25, 2023

    Hepatocellular Carcinoma (HCC) · TERMINATED · sponsor: Great Novel Therapeutics Biotech & Medicals Corporation · Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

    ClinicalTrials.gov · NCT05770882 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources